NCT02788227View on ClinicalTrials.gov

Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

June 17, 2025

Study Completion Date

June 17, 2025

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

rVSV-Zebov GP vaccine

primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02788227 - Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure | Biotech Hunter | Biotech Hunter